3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPF

Inclusion criteria

• ✓. A confirmed diagnosis of COPD by the Global initiative for chronic Obstructive Lung Disease (GOLD) criteria
• ✓. Pulmonary hypertension determined by one of the following within the past 12 months:
• ✓. A right heart catheterization (not obtained within ± 7 days of an exacerbation) with an mPAP ≥ 25 mmHg, or
• ✓. An echocardiogram (not obtained within ± 7 days of an exacerbation) with a TRV ≥ 2.9 m/s or sPAP ≥ 38 mmHg (Note: a subject with an acceptable mPAP ≥ 25 mmHg determined by right heart catheterization will meet this inclusion criteria even with a TRV \< 2.9 m/s)
• ✓. Current or former smokers with at least 10 pack-years of tobacco cigarette smoking before study entry
• ✓. Age ≥ 40 years, ≤ 80 years
• ✓. A post-bronchodilatory FEV1/FVC \< 0.7 and a FEV1 \< 60% predicted (values obtained within 6 months prior to screening can be used unless obtained within ± 7 days of an exacerbation; otherwise, the test must be performed during screening)
• ✓. Receiving LTOT for ≥ 3 months and ≥ 10 hours per day as determined by history

Exclusion criteria